A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

This study is testing a combination of daratumumab (a targeted antibody drug) and a chemotherapy regimen called dose-adjusted EPOCH for a rare and aggressive blood cancer called plasmablastic lymphoma. **You may be eligible if...** - You have a confirmed diagnosis of plasmablastic lymphoma, stage II-IV (or stage I with elevated markers or a large tumor) - You are HIV-positive or HIV-negative (up to 7 HIV-negative patients will be enrolled) - If HIV-positive, your CD4 count is at least 100 cells/mL and you are on or willing to start effective HIV treatment (HAART) - Your blood counts and organ function are within acceptable levels - Your heart function (ejection fraction) is 45% or above - You agree to use effective contraception during and for 90 days after treatment **You may NOT be eligible if...** - You have had prior chemotherapy for this lymphoma (with limited exceptions) - You have previously received daratumumab - You have active hepatitis B or hepatitis C with cirrhosis - You have brain involvement from lymphoma - You are pregnant or breastfeeding - You have severe heart, lung, or other serious medical conditions Talk to your doctor to see if this trial is right for you.